A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

@article{Lim2014API,
  title={A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.},
  author={Ho-yeong Lim and Jeong Heo and Hye Jin Choi and Cheng-Yao Lin and Jung-Hwan Yoon and C Hsu and K M Rau and Ronnie Tung-ping Poon and Winnie Yeo and Joong-Won Park and Miah Hiang Tay and Wen-son Hsieh and Christian Kappeler and P. Rajagopalan and Heiko Krissel and Michael E. Jeffers and C N Yen and Won Young Tak},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 23},
  pages={5976-85}
}
PURPOSE There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved systemic treatment for HCC. Refametinib, an oral, allosteric MEK inhibitor, has demonstrated antitumor activity in combination with sorafenib in vitro and in vivo. A phase II study evaluated efficacy and safety of refametinib plus sorafenib in Asian patients with HCC (NCT01204177). EXPERIMENTAL DESIGN Eligible patients received twice-daily refametinib 50 mg plus… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
21 Citations
19 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Cancer statistics ,

  • D Naishadham
  • 2012

Ef fi cacy and safety of sorafenib in patients in the Asia - Paci fi c region with advanced hepatocellular carcinoma : a phase III randomised , double - blind , placebo - controlled trial

  • KangYK ChengAL, TsaoCJ ChenZ, S Qin, KimJS
  • Lancet Oncol
  • 2009

Similar Papers

Loading similar papers…